Cat. No.: HY-17424

Penciclovir

(Synonyms: BRL 39123; VSA 671)

1 Cited Publications

Customer Review

Based on 1 publication(s) in Google Scholar

Penciclovir (VSA 671) is a potent and selective anti-herpesvirus agent with EC₅₀ values of 0.5, 0.8 μg/ml for HSV-1 (HFEM), HSV-2 (MS), respectively. Penciclovir shows anti-herpesvirus activity with no-toxic. Penciclovir preventes mortality in mouse.

For research use only. We do not sell to patients.

Purity: 99.81%
CAS No.: 39809-25-1
Formula: C₁₀H₁₅N₅O₃
Molecular Weight:253.26

Storage:

Powder -20°C, 3 years , 4°C, 2 years ; In solvent -80°C, 2 years , -20°C, 1 year

Penciclovir Chemical Structure

CAS No.: 39809-25-1

Size

Price

Stock

Quantity

Sample (0.1mg)

In-stock

(In Japan)

Apply Now

Get Quote Ask For Quote & Lead Time Consult sales personnel for more information Check price and availability Get Quote Ask For Quote & Lead Time Consult sales personnel for more information Check price and availability

Bulk Inquiry

Amount: USD 0.00

* Please select Quantity before adding items.

Top Publications Citing

Use of MCE Products

Fluorescent Dye

Strong Fluorescence Signal / Multi-Disciplinary Applications / High Fluorescence Specificity

Biological Activity
- Description
- IC₅₀ & Target
- Cellular Effect
- In Vitro
- In Vivo
Chemical Information
Publications (1)
Solvent & Solubility
- In Vitro
- In Vivo
Purity & Documentation
References
Help & FAQs
Bioz

Biological Activity

Description

IC₅₀ & Target^[1]

HSV-1

HSV-2

HSV-1

0.5 μg/mL (EC₅₀)

HSV-2

0.8 μg/mL (EC₅₀)

All HSV Isoforms :

Cellular Effect

Cell Line	Type	Value	Description	References
CAPAN-1	IC₅₀	93 μM Compound: 6; PCV	Cytostatic activity against human Capan1 cells Cytostatic activity against human Capan1 cells	[PMID: 30738653]
HEL	CC₅₀	>100 μM Compound: 2	Cytotoxicity against human HEL cells assessed as cell growth inhibition by cell counting method Cytotoxicity against human HEL cells assessed as cell growth inhibition by cell counting method	[PMID: 28829913]
HEL	CC₅₀	>395 μM Compound: Penciclovir	Cytotoxicity against HEL cells assessed as reduction in cell viability after 3 days by coulter counting method Cytotoxicity against HEL cells assessed as reduction in cell viability after 3 days by coulter counting method	[PMID: 29670705]
HEL	IC₅₀	10 μg/mL Compound: PCV	Tested for Antiherpetic activity against VZV from clinical isolates of HEL cell lines.(average of 11 isolates) Tested for Antiherpetic activity against VZV from clinical isolates of HEL cell lines.(average of 11 isolates)	[PMID: 10649983]
HEL	IC₅₀	5.6 μg/mL Compound: PCV	Tested for Antiherpetic activity against VZV from Kawaguchi strain in HEL cell lines. Tested for Antiherpetic activity against VZV from Kawaguchi strain in HEL cell lines.	[PMID: 10649983]
Hepatocyte	EC₅₀	0.3 μg/mL Compound: PCV- Penciclovir	Concentration required to reduce the viral DNA in infected cells to 50% of untreated infected controls of Hepatitis B virus in primary duck hepatocyte (DHBV) cultures. Concentration required to reduce the viral DNA in infected cells to 50% of untreated infected controls of Hepatitis B virus in primary duck hepatocyte (DHBV) cultures.	[PMID: 11985471]
HepG2	EC₅₀	>=100 μM Compound: 3 Penciclovir	Tested for the effective concentration required to inhibit HBV in HepG2.2.15 human liver cells Tested for the effective concentration required to inhibit HBV in HepG2.2.15 human liver cells	10.1016/S0960-894X(96)00594-X
HepG2	EC₅₀	0.19 μM Compound: Penciclovir (PCV)	Effective concentration necessary to decrease extracellular Hepatitis B virus DNA levels by 50% in human hepatoblastoma cell line (2.2.15 cells) in vitro Effective concentration necessary to decrease extracellular Hepatitis B virus DNA levels by 50% in human hepatoblastoma cell line (2.2.15 cells) in vitro	10.1016/S0960-894X(97)00422-8
HepG2	IC₅₀	433 μM Compound: Penciclovir (PCV)	Cytotoxicity towards human hepatoblastoma cell line (2.2.15 cells) measured by inhibition of neutral red dye uptake in vitro Cytotoxicity towards human hepatoblastoma cell line (2.2.15 cells) measured by inhibition of neutral red dye uptake in vitro	10.1016/S0960-894X(97)00422-8
HepG2 2.2.15	CC₅₀	552 μM Compound: Penciclovir	Cytotoxicity against human HepG2(2.2.15) cells by neutral red dye uptake assay Cytotoxicity against human HepG2(2.2.15) cells by neutral red dye uptake assay	[PMID: 21333535]
HepG2 2.2.15	EC₅₀	3.4 μM Compound: Penciclovir	Antiviral activity against Hepatitis B virus infected in human HepG2(2.2.15) cells assessed as reduction in viral DNA by Southern blotting Antiviral activity against Hepatitis B virus infected in human HepG2(2.2.15) cells assessed as reduction in viral DNA by Southern blotting	[PMID: 21333535]
HL-60	IC₅₀	>100 μM Compound: 6; PCV	Cytostatic activity against human HL60 cells Cytostatic activity against human HL60 cells	[PMID: 30738653]
HSV-2	ED₅₀	12 μg/mL Compound: 2b(c-GCV)	Antiviral activity against HSV-2 cell line (concentration required to prevent viral cytopathic effect in half of primary rabbit kidney cell cultures) Antiviral activity against HSV-2 cell line (concentration required to prevent viral cytopathic effect in half of primary rabbit kidney cell cultures)	[PMID: 2848125]
K562	IC₅₀	>100 μM Compound: 6; PCV	Cytostatic activity against human K562 cells Cytostatic activity against human K562 cells	[PMID: 30738653]
MRC5	IC₅₀	>100 μM Compound: Pentacyclovir	Inhibitory activity against human cytomegalovirus (HCMV) strain AD169 in MRC-5 cells. Inhibitory activity against human cytomegalovirus (HCMV) strain AD169 in MRC-5 cells.	[PMID: 8576922]
MRC5	IC₅₀	0.54 μg/mL Compound: PCV	Tested for Antiherpetic activity against HSV-1 from Tomioka strain in MRC-5 cell lines. Tested for Antiherpetic activity against HSV-1 from Tomioka strain in MRC-5 cell lines.	[PMID: 10649983]
MRC5	IC₅₀	1.2 μg/mL Compound: PCV	Tested for Antiherpetic activity against HSV-2 from 186 strain in MRC-5 cell lines. Tested for Antiherpetic activity against HSV-2 from 186 strain in MRC-5 cell lines.	[PMID: 10649983]
MRC5	IC₅₀	16 μM Compound: Penciclovir	Antiviral activity against Varicella zoster virus Ellen infected in human MRC5 cells assessed as inhibition of viral replication by viral reduction plaque assay Antiviral activity against Varicella zoster virus Ellen infected in human MRC5 cells assessed as inhibition of viral replication by viral reduction plaque assay	[PMID: 23219702]
MRC5	IC₅₀	78.7 μM Compound: Pentacyclovir	Inhibitory activity against varicella zoster virus (VZV) strain G31 in MRC-5 cells. Inhibitory activity against varicella zoster virus (VZV) strain G31 in MRC-5 cells.	[PMID: 8576922]
MT4	IC₅₀	>150 μM Compound: 2	Cytotoxicity against human MT4 cells assessed as reduction in cell viability by cell counting method Cytotoxicity against human MT4 cells assessed as reduction in cell viability by cell counting method	[PMID: 28829913]
NCI-H460	IC₅₀	>100 μM Compound: 6; PCV	Cytostatic activity against human NCI-H460 cells Cytostatic activity against human NCI-H460 cells	[PMID: 30738653]
TERT-RPE1	IC₅₀	>100 μM Compound: 6; PCV	Cytostatic activity against human hTERT-RPE1 cells Cytostatic activity against human hTERT-RPE1 cells	[PMID: 30738653]
Vero	CC₅₀	>500 μM Compound: penciclovir	Compound was tested for cytotoxicity in Vero cells (concentration required to reduce the OD value by 50% of the control) Compound was tested for cytotoxicity in Vero cells (concentration required to reduce the OD value by 50% of the control)	[PMID: 9719596]
Vero	CC₅₀	>790 μM Compound: PCV	Cytotoxicity against african green monkey Vero cells after 2 days Cytotoxicity against african green monkey Vero cells after 2 days	[PMID: 17438061]
Vero	EC₅₀	17 μM Compound: PCV	Antiviral activity against Herpes B virus 24105 infected in african green monkey Vero cells assessed as plaque reduction after 36 to 48 hrs Antiviral activity against Herpes B virus 24105 infected in african green monkey Vero cells assessed as plaque reduction after 36 to 48 hrs	[PMID: 17438061]
Vero	EC₅₀	17.3 μM Compound: PCV	Antiviral activity against Herpes B virus E90-136 infected in african green monkey Vero cells assessed as plaque reduction after 36 to 48 hrs Antiviral activity against Herpes B virus E90-136 infected in african green monkey Vero cells assessed as plaque reduction after 36 to 48 hrs	[PMID: 17438061]
Vero	EC₅₀	25.3 μM Compound: PCV	Antiviral activity against Herpes B virus 32425 infected in african green monkey Vero cells assessed as plaque reduction after 36 to 48 hrs Antiviral activity against Herpes B virus 32425 infected in african green monkey Vero cells assessed as plaque reduction after 36 to 48 hrs	[PMID: 17438061]
Vero	EC₅₀	4.7 μM Compound: PCV	Antiviral activity against Herpes simplex virus 1 F infected in african green monkey Vero cells assessed as plaque reduction after 36 to 48 hrs Antiviral activity against Herpes simplex virus 1 F infected in african green monkey Vero cells assessed as plaque reduction after 36 to 48 hrs	[PMID: 17438061]
Vero	EC₅₀	8.1 μM Compound: Penciclovir	Compound was tested for its antiviral activity against HSV-1(KOS strain) in vero cells Compound was tested for its antiviral activity against HSV-1(KOS strain) in vero cells	10.1016/0960-894X(96)00329-0
Vero	IC₅₀	12.8 μM Compound: Pentacyclovir	Inhibitory activity against herpes simplex virus type 2 (HSV 2) strain 186 in Vero cells. Inhibitory activity against herpes simplex virus type 2 (HSV 2) strain 186 in Vero cells.	[PMID: 8576922]
Vero	IC₅₀	3.9 μM Compound: Pentacyclovir	Inhibitory activity against herpes simplex virus type 1 (HSV-1) strain SC16 in Vero cells. Inhibitory activity against herpes simplex virus type 1 (HSV-1) strain SC16 in Vero cells.	[PMID: 8576922]
Vero	IC₅₀	6.4 μM Compound: 1	Compound was tested for antiviral activity against Herpes Simplex virus Type-1(HFEM) in vero cells Compound was tested for antiviral activity against Herpes Simplex virus Type-1(HFEM) in vero cells	[PMID: 3040998]
Vero	IC₅₀	6.4 μM Compound: 1	Compound was tested for antiviral activity against Herpes Simplex virus Type-2(MS) in vero cells Compound was tested for antiviral activity against Herpes Simplex virus Type-2(MS) in vero cells	[PMID: 3040998]
Vero C1008	CC₅₀	>400 μM Compound: 50	Cytotoxicity against African green monkey Vero E6 cells by the CCK8 assay Cytotoxicity against African green monkey Vero E6 cells by the CCK8 assay	[PMID: 32845145]
Vero C1008	CC₅₀	>400 μM Compound: 54	Cytotoxicity against African green monkey Vero E6 cells by CCK-8 assay Cytotoxicity against African green monkey Vero E6 cells by CCK-8 assay	[PMID: 33486200]
Vero C1008	CC₅₀	>400 μM Compound: Penciclovir	Cytotoxicity against African green monkey Vero E6 cells by CCK8 assay Cytotoxicity against African green monkey Vero E6 cells by CCK8 assay	[PMID: 32511912]
Vero C1008	CC₅₀	>400 μM Compound: Penciclovir	Cytotoxicity against African green monkey Vero E6 cells assessed as reduction of cell viability measured after 48 hrs by CCK-8 assay Cytotoxicity against African green monkey Vero E6 cells assessed as reduction of cell viability measured after 48 hrs by CCK-8 assay	[PMID: 32563814]
Vero C1008	EC₅₀	95.96 μM Compound: 54	Antiviral activity against SARS-CoV infected in Vero E6 cells assessed as reduction in viral replication measured after 48 hrs by qRT-PCR assay Antiviral activity against SARS-CoV infected in Vero E6 cells assessed as reduction in viral replication measured after 48 hrs by qRT-PCR assay	[PMID: 33486200]
Z-138	IC₅₀	>100 μM Compound: 6; PCV	Cytostatic activity against human Z138 cells Cytostatic activity against human Z138 cells	[PMID: 30738653]

In Vitro

Penciclovir (0-100 μg/ml) shows anti-herpesvirus activity with EC₅₀s of 0.5, 0.8, 2.4, 52, 100, 1.2, 1.6, 0.9, >100 μg/ml for HSV-1 (HFEM), HSV-2 (MS), VZV (Ellen), CMV (AD-169), BHV-1 (Oxford 1964), BHV-2 (New York 1), EHV-1(Quai Hals), FHV-1 (B927), SVV, respectively^[1].
Penciclovir (0-100 μg/ml) shows no-toxic to uninfected human cells^[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Cell Cytotoxicity Assay^[1]

Cell Line:

MRC-5,WISH, Flow 4000, Flow 12000, RPMI 2650, WI-38, WI-38 VA13, Hs68, HEp-2, RD, SCC-13,Primary cells
Concentration:

0-100 µg/ml
Incubation Time:
Result:

Showed no-toxic with IC₅₀s of >100, >100, 100, >100, 60, >100, >100, >100, >100, >100, >100, >100 for MRC-5,WISH, Flow 4000, Flow 12000, RPMI 2650, WI-38, WI-38 VA13, Hs68, HEp-2, RD, SCC-13,Primary cells, respectively.

In Vivo

Penciclovir (100 mg/kg; s.c.; daily for 5 days) preventes mortality in mouse^[2].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:

Three-week-old female Balb/c mice^[2]
Dosage:

100 mg/kg
Administration:

S.c.; daily for 5 days
Result:

Reduced virus titres in the respiratory organs of both w/t- and PR3-infected mice.

Chemical Information

CAS No. 39809-25-1
Appearance Solid
Molecular Weight 253.26
Formula C₁₀H₁₅N₅O₃
Color White to off-white
SMILES

O=C1NC(N)=NC2=C1N=CN2CCC(CO)CO
Synonyms

BRL 39123; VSA 671
Shipping

Room temperature in continental US; may vary elsewhere.

Storage

Powder	-20°C	3 years
	4°C	2 years
In solvent	-80°C	2 years
	-20°C	1 year

Publications (1)

All

Sort by:

Journal Impact Factor

Microchem J

2021, 106587.

Solvent & Solubility

In Vitro:

DMSO : 25 mg/mL (98.71 mM; Need ultrasonic; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)

H₂O : 2 mg/mL (7.90 mM; ultrasonic and warming and heat to 60°C)

View the Complete Stock Solution Preparation Table

Preparing Stock Solutions

View the Complete Stock Solution Preparation Table

Concentration Solvent Mass

1 mg

5 mg

10 mg

Concentration

Solvent

Mass

1 mM

3.9485 mL

19.7426 mL

39.4851 mL

5 mM

0.7897 mL

3.9485 mL

7.8970 mL

10 mM

0.3949 mL

1.9743 mL

3.9485 mL

Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.

Storage method and period of stock solution: -80°C, 2 years; -20°C, 1 year. When stored at -80°C, please use it within 2 years. When stored at -20°C, please use it within 1 year.

* Note: If you choose water as the stock solution, please dilute it to the working solution, then filter and sterilize it with a 0.22 μm filter before use.

Molarity Calculator

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Mass Mass

Concentration Concentration

Volume Volume

Molecular Weight Molecular Weight

Dilution Calculator

Concentration _(start) × Volume _(start) = Concentration _(final) × Volume _(final)

Concentration _(start) Concentration _(start)

Volume _(start) Volume _(start)

Concentration _(final) Concentration _(final)

Volume _(final) Volume _(final)

In Vivo:

Select the appropriate dissolution method based on your experimental animal and administration route.

Stock Solution Working Solution

For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for In Vivo experiments, it is recommended to prepare freshly and use it on the same day.
The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.

Protocol 1

Add each solvent one by one: 10% DMSO 40% PEG300 5% Tween-80 45% Saline

Solubility: ≥ 2.5 mg/mL (9.87 mM); Clear solution

This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown).

Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 400 μL PEG300, and mix evenly; then add 50 μL Tween-80 and mix evenly; then add 450 μL Saline to adjust the volume to 1 mL.

Protocol 2

Add each solvent one by one: 10% DMSO 90% (20% SBE-β-CD in Saline)

Solubility: ≥ 2.5 mg/mL (9.87 mM); Clear solution

This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown).

Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 900 μL 20% SBE-β-CD in Saline, and mix evenly.

Protocol 3

Add each solvent one by one: 10% DMSO 90% Corn Oil

Solubility: ≥ 2.5 mg/mL (9.87 mM); Clear solution

This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown). If the continuous dosing period exceeds half a month, please choose this protocol carefully.

Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 900 μL Corn oil, and mix evenly.

In Vivo Dissolution Calculator

Please enter the basic information of animal experiments:

Dosage Dosage
mg/kg
Animal Weight (Per Animal) Animal Weight (Per Animal)
g
Dosing Volume (Per Animal) Dosing Volume (Per Animal)
μL
Number of Animals Number of Animals

Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.

Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.

Please enter your animal formula composition:

%
DMSO +

Recommended: Keep the proportion of DMSO in working solution below 2% if your animal is weak.
%
+
+
%
Tween-80 + +
%
Saline +

The co-solvents required include: DMSO, . All of co-solvents are available by MedChemExpress (MCE). , Tween 80. All of co-solvents are available by MedChemExpress (MCE).

Working solution concentration: 0.22 mg/mL

Purity & Documentation

Select Batch:

Purity: 99.98%

Assay: 99.98%

ee.: 99.98%

Data Sheet (275 KB)
SDS (396 KB)
- English - EN (396 KB)
- Français - FR (396 KB)
- Deutsch - DE (396 KB)
- Norwegian - NO (396 KB)
- Español - ES (396 KB)
- Swedish - SV (396 KB)
- Italian - IT (396 KB)
- Portuguese - PT (396 KB)
COA (2659 KB)
Elemental Analysis Report (2659 KB)
HNMR (2659 KB)
CNMR (2659 KB)
RP-HPLC (2659 KB)
NP-HPLC (2659 KB)
MS (2659 KB)
LCMS (2659 KB)
IR (2659 KB)
GC (2659 KB)
OR (2659 KB)
SDS-PAGE (2659 KB)
SEC-HPLC (2659 KB)
Other Report (2659 KB)
Handling Instructions (2659 KB)

References

[1]. M.R. Boyd, et al. Penciclovir: a review of its spectrum of activity, selectivity, and cross-resistance pattern. Antiviral Chemistry and Chemotherapy, 1993, (1): 3-11.

[2]. de la Fuente R, et al. The acyclic nucleoside analogue penciclovir is a potent inhibitor of equine herpesvirus type 1 (EHV-1) in tissue culture and in a murine model. Antiviral Res. 1992 May;18(1):77-89. [Content Brief]

Help & FAQs

How should lyophilized recombinant proteins be reconstituted and stored?

1. Before opening the cap, centrifuge the vial at 13000 rpm for 20-30 seconds. This step will ensure that any lyophilized powder that may have adhered to the cap or walls is collected at the bottom of the vial, minimizing the risk of product loss.

Complete Stock Solution Preparation Table

Storage method and period of stock solution: -80°C, 2 years; -20°C, 1 year. When stored at -80°C, please use it within 2 years. When stored at -20°C, please use it within 1 year.

Optional Solvent	Concentration Solvent Mass	1 mg	5 mg	10 mg	25 mg
H₂O / DMSO	1 mM	3.9485 mL	19.7426 mL	39.4851 mL	98.7128 mL
H₂O / DMSO	5 mM	0.7897 mL	3.9485 mL	7.8970 mL	19.7426 mL
DMSO	10 mM	0.3949 mL	1.9743 mL	3.9485 mL	9.8713 mL
	15 mM	0.2632 mL	1.3162 mL	2.6323 mL	6.5809 mL
	20 mM	0.1974 mL	0.9871 mL	1.9743 mL	4.9356 mL
	25 mM	0.1579 mL	0.7897 mL	1.5794 mL	3.9485 mL
	30 mM	0.1316 mL	0.6581 mL	1.3162 mL	3.2904 mL
	40 mM	0.0987 mL	0.4936 mL	0.9871 mL	2.4678 mL
	50 mM	0.0790 mL	0.3949 mL	0.7897 mL	1.9743 mL
	60 mM	0.0658 mL	0.3290 mL	0.6581 mL	1.6452 mL
	80 mM	0.0494 mL	0.2468 mL	0.4936 mL	1.2339 mL

* Note: If you choose water as the stock solution, please dilute it to the working solution, then filter and sterilize it with a 0.22 μm filter before use.

Keywords

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent:

Product Name:
CAS No.:
Species:
Purity:
Quantity:

Penciclovir

Anti-Infection Compound Library

FDA-Approved Drug Library

Antiviral Compound Library

Drug Repurposing Compound Library

Anti-COVID-19 Compound Library

NMPA-Approved Drug Library

FDA Approved & Pharmacopeial Drug Library

Rare Diseases Drug Library

Human Metabolite Library

Off-patent Drug Library

Highly Selective Inhibitors Library

Multi-Target Compound Library

Bioactive Compound Library Max

MCE Bioactive Compound Library

Drug Repurposing Compound Library Plus

FDA-Approved Drug Library Plus

FDA-Approved Drug Library Mini

Bioactive Compound Library

High-Throughput Bioactive Compound Library

MCE Kinase Hinge Binder Fragment Library

Publications Citing Use of MedChemExpress (MCE) Penciclovir

All HSV Isoforms

Biological Activity

Chemical Information

Publications (1)

Solvent & Solubility

Purity & Documentation

References

Help & FAQs

Complete Stock Solution Preparation Table

Penciclovir

Anti-Infection Compound Library

FDA-Approved Drug Library

Antiviral Compound Library

Drug Repurposing Compound Library

Anti-COVID-19 Compound Library

NMPA-Approved Drug Library

FDA Approved & Pharmacopeial Drug Library

Rare Diseases Drug Library

Human Metabolite Library

Off-patent Drug Library

Highly Selective Inhibitors Library

Multi-Target Compound Library

Bioactive Compound Library Max

MCE Bioactive Compound Library

Drug Repurposing Compound Library Plus

FDA-Approved Drug Library Plus

FDA-Approved Drug Library Mini

Bioactive Compound Library

High-Throughput Bioactive Compound Library

MCE Kinase Hinge Binder Fragment Library

Publications Citing Use of MedChemExpress (MCE) Penciclovir

All HSV Isoforms

Biological Activity

Chemical Information

Publications (1)

Solvent & Solubility

Purity & Documentation

References

Help & FAQs

Complete Stock Solution Preparation Table

Penciclovir Related Classifications

Cat. No.: HY-17424